泽璟制药：注射用ZGGS34获药物临床试验批准通知书

Group 1 - The core point of the article is that Zai Lab (688266) has received approval from the National Medical Products Administration for a clinical trial of its drug ZGGS34, which is intended for MUC17 positive advanced solid tumors [1] Group 2 - The clinical trial approval signifies a potential advancement in treatment options for patients with MUC17 positive advanced solid tumors [1]